Combined Effects of Bioactive Compounds (ARMOLIPID PLUS) on Lipid Profile and Clinical Criteria of Metabolic Syndrome in Patients With Serum Elevated LDL-C
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Astaxanthin/berberine/folic acid/monascus/policosanol/ubidecarenone (Primary)
- Indications Hypercholesterolaemia; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms ARM-PLUS-LDL
- 28 Feb 2013 Biomarkers information updated
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Mar 2012 New trial record